November 22, 2024

DealBook: Antitrust Agreement in Merger of Anheuser-Busch and Brewer of Corona

Constellation will get rights to make and sell Corona.Victor Ruiz Garcia/ReutersConstellation will get rights to make and sell Corona.

7:26 p.m. | Updated

WASHINGTON — Anheuser-Busch InBev, the country’s largest brewer, agreed on Friday to sell the United States rights to several foreign brands, including the top-selling Corona, in a deal that regulators say will ensure competition in beer prices.

The settlement of the Justice Department’s antitrust lawsuit means that Anheuser-Busch InBev, which controls 39 percent of the American beer market, can go ahead with its $20.1 billion takeover of Grupo Modelo of Mexico, the brewer of Corona.

But as part of the agreement, Anheuser will sell Modelo’s 50 percent stake in Crown Imports, which distributes Corona and other Modelo brands in the United States, to Constellation Brands, which already owned the other half.

Related Links



For American consumers, the agreement will help keep beer prices down, government officials say, although there will be little practical effect on what beer buyers will see when they go shopping.

“This is an $80 billion market,” said William J. Baer, an assistant attorney general who oversees the Justice Department’s antitrust division. “Even a 1 percent price change would cost consumers $1 billion a year. This agreement will help to keep the market competitive, dynamic and quite healthy.”

The Justice Department’s antitrust division filed a lawsuit in January to block the merger. The government’s opposition was a big blow to Anheuser-Busch InBev, which saw the acquisition as vital to its push to expand in Mexico and the rest of Latin America. In February, the two sides announced they were in talks to resolve the antitrust concerns.

The settlement will leave Constellation — one of the country’s largest wine producers — with full and permanent rights to make and sell Corona, Corona Light, Modelo Especial, Pacifico and six other brands in the United States.

“Ultimately, nothing will change for consumers in the U.S. as a result of this transaction,” said Laura Vallis, a spokeswoman for Anheuser-Busch InBev. “The proposed combination with Grupo Modelo has always been about Mexico, and making Corona more global in markets other than the United States. Beers that Mexican consumers enjoy and appreciate will now get a larger worldwide presence.”

Constellation will pay $5.5 billion for Modelo’s share of Crown and for the Piedras Negras brewery, a new production and bottling plant in Mexico near the border with Texas.

Rob Sands, president and chief executive of Constellation, called the deal “the most transformational event in the history of our 68-year-old company,” one that would double sales and significantly increase profits and free cash flow.

Anheuser-Busch InBev is itself the result of a $52 billion merger in 2008 between the maker of Budweiser and a Belgian-Brazilian brewer. It was looking to expand internationally, and wanted to secure the rights to sell Corona and Modelo’s other Mexican brands around the world, particularly in Europe and South America.

Corona is the top-selling imported beer in the United States and the fifth-largest seller over all. Few imports to Europe, analysts say, have a greater potential for growth there.

But the Justice Department decided that in the United States, joining the marketing of Corona with that of Bud Light, the country’s biggest seller, and other top brands would result in too much consolidation and too little price competition.

A merger of the 39 percent market share of Anheuser-Busch InBev, also known as ABI, with Modelo’s brands, which account for 7 percent of the United States market, would put 46 percent of the market in one company’s hands.

That would essentially make the United States beer market a duopoly, because MillerCoors, the second-largest brewer of beer sold in the United States, controls 26 percent of the market. The next largest company would be Heineken USA at 6 percent.

But even those large market shares understate the effect of the market power of the two largest companies, which tend to “engage in significant levels of tacit coordination” in pricing, the Justice Department said. Anheuser would usually raise prices in the fall, and shortly thereafter MillerCoors would follow suit, often with the same increase, the regulators said.

In certain geographic market areas, however, Modelo accounts for as much as 20 percent of sales, and that gives it a unique ability to enforce price competition on the larger companies in those markets.

From 2010 to 2012, the Justice Department said in its lawsuit, aggressive pricing by Modelo in California, Texas and New York City kept Anheuser from raising prices, forced it to lower prices or caused it to lose market share.

The new arrangement will keep the Modelo brands competing with Anheuser-Busch InBev’s products in the United States. Constellation has never brewed beer, however, making the deal a new direction for the company. Currently, it produces and markets wine and spirits, including Robert Mondavi and Clos du Bois wines and Svedka vodka.

Constellation will gain control of a new, state-of-the-art brewery that is about at the midpoint of the 1,240-mile border between Texas and Mexico. The company plans to nearly double the plant’s capacity to take over the brewing of Modelo products for the United States.

Article source: http://dealbook.nytimes.com/2013/04/19/anheuser-busch-reaches-deal-with-antitrust-regulators/?partner=rss&emc=rss

Mortgage Executive Guilty in $3 Billion Fraud

After more than a day of deliberations, a federal jury in Virginia found Lee B. Farkas, the chairman of Taylor, Bean Whitaker, guilty on 14 counts of securities, bank and wire fraud and conspiracy to commit fraud. Mr. Farkas faces decades in prison for his role in the $2.9 billion plot, which prosecutors say was one of the largest and longest bank fraud schemes in American history and led to the 2009 collapse of Colonial Bank.

 “There’s no question that it is very momentous and a very significant case,” Lanny Breuer, an assistant attorney general, said on Tuesday.

The 10-day trial was the rare win for federal prosecutors in the aftermath of the financial mess. The Justice Department has yet to bring charges against an executive who ran a major Wall Street firm leading up to the disaster. An earlier case against hedge fund managers at Bear Stearns ended in acquittal. Prosecutors dropped their investigation into Angelo R. Mozilo, the former chief executive of Countrywide Financial, which nearly collapsed under the weight of souring subprime home loans.

Six other Taylor, Bean Whitaker executives — including its former chief executive and former treasurer — have already pleaded guilty. Some agreed to testify against Mr. Farkas at his trial.

Mr. Farkas took the stand during the trial to defend his actions and deny any wrongdoing. A lawyer for Mr. Farkas did not respond to a request for comment. 

 The Securities and Exchange Commission has also sued Mr. Farkas. That case continues.

The scheme began in 2002, prosecutors say, when Taylor, Bean Whitaker executives moved to hide the firm’s losses, secretly overdrawing its accounts at Colonial Bank by more than $100 million. To cover up the actions, the lender sold Colonial some $1.5 billion in “worthless” and “fake” mortgages, prosecutors said at trial. The government, in turn, guaranteed those fraudulent home loans.

During the course of the fraud, prosecutors said, Mr. Farkas pocketed some $20 million, which he used to buy a private jet, five homes and a collection of vintage cars.

 “His shockingly brazen scheme poured fuel on the fire of the financial crisis,” Mr. Breuer said.  

With the credit crisis in full swing, Mr. Farkas and other Taylor, Bean Whitaker executives persuaded Colonial to apply for $570 million in federal bailout funds through the Troubled Asset Relief Program. The Treasury Department approved the rescue funds, on the condition that the bank was able to raise $300 million in private funds. The Taylor, Bean Whitaker executives falsely led Colonial into thinking that was possible. Ultimately, the government did not give any money to Colonial. 

“Today’s verdict ensures that Farkas will pay for his crime — an unprecedented scheme to defraud regulators during the height of the financial crisis and to steal over $550 million from the American taxpayers through TARP,” Christy Romero, the acting special inspector general for the TARP program, said in a statement.

In August 2009, Colonial filed for bankruptcy, the same time that Taylor, Bean Whitaker failed.

 

 

Article source: http://feeds.nytimes.com/click.phdo?i=e575d25655491ac402c5823ed83caa70

U.S. Chemist Is Charged With Insider Stock Trades

The charges were made in a criminal complaint filed by the Justice Department against Cheng Yi Liang, 57, and his son, Andrew Liang, both residents of Gaithersburg, Md. The Securities and Exchange Commission simultaneously filed a civil securities fraud complaint against the elder Mr. Liang.

Timothy Sullivan, a lawyer for Andrew Liang, declined to comment on the charges. Andrew Carter, a federal public defender temporarily assigned to represent Cheng Yi Liang, did not respond to calls seeking comment.

The cases, filed in Federal District Court in Greenbelt, Md., cited trades in the stock of five pharmaceutical companies whose products were undergoing review at the F.D.A.’s Office of New Drug Quality Assessment, where the elder Mr. Liang worked as a chemist. His job gave him access to a password-protected database that tracked the status of new drugs under review.

The criminal complaint accused him of using that database to get an early look at F.D.A. decisions on companies developing drugs and then working with his son to trade on that knowledge, buying stock ahead of good news and selling it before bad news was announced.

The complaints assert that the defendants made just under $2.3 million in direct profits and avoided an additional $1.3 million in losses.

In a statement announcing the case, Lanny A. Breuer, the assistant attorney general for the criminal division, said: “Cheng Yi Liang was entrusted with privileged information to perform his job of ensuring the health and safety of his fellow citizens. According to the complaint, he and his son repeatedly violated that trust to line their own pockets.”

Law enforcement veterans said the case was unusual on several fronts. First, it is uncommon for insider-trading investigations to involve the F.D.A., despite the significant amount of market-moving information that passes through the agency each year. The agency maintains a rigorous ethics code and imposes significant restrictions on stock ownership and trading by its employees.

The case is also noteworthy, Mr. Breuer said, for its application of computer technology. Investigators used hidden software installed on Mr. Liang’s computer to track his visits to the confidential database and match those visits against his trading activity in accounts he had set up in the names of friends and relatives in Maryland, China and Japan.

It is not clear from the complaint what drew the attention of law enforcement, but clearly, something in January prompted investigators to install tracking software on Mr. Liang’s computer.

According to the complaint, the hidden software revealed that Mr. Liang had tapped into the database on Jan. 18 and reviewed an internal F.D.A. document recommending approval of Viibryd, an antidepressant drug submitted to the agency by Clinical Data

The complaint asserted that, within minutes, several accounts controlled by Mr. Liang and his son had bought 4,875 shares of Clinical Data’s stock. According to prosecutors, the Liangs accumulated 48,875 shares of Clinical Data stock before Viibryd’s approval was announced on Jan. 21, and subsequently sold their entire stake for a profit of more than $379,000.

The complaint also accuses the Liangs of trading in advance of a May 6, 2009, announcement by Vanda Pharmaceuticals that the F.D.A. had approved its drug Fanapt.  Using Andrew Liang’s account and several other accounts, the Liangs are accused of netting more than $1 million, for a profit of nearly 800 percent.

The other companies whose stock was affected by the trading were Progenics Pharmaceuticals, Middlebrook Pharmaceuticals and Momenta Pharmaceuticals.

The S.E.C. complaint accused the elder Mr. Liang of illegally trading ahead of more than two dozen F.D.A. announcements involving drug applications by 19 companies. It seeks to recover profits from him, from his son and from five other defendants, including Mr. Liang’s wife and mother.

Article source: http://feeds.nytimes.com/click.phdo?i=22490f662305eb2c3e33b26f5c5e44ef